Chemical: Drug
coumarin

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for coumarin

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2A6 *1A N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *4A N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *4B N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *4C N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *4D N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *5 N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *6 N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *7 N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *9 N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *9A N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *10 N/A N/A N/A
VIP No VIP available VA CYP2A6 *12A N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *18A N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *19 N/A N/A N/A
No VIP available No VIP available VA CYP2A6 *20 N/A N/A N/A
VIP No VIP available No VIP available VKORC1 *1 N/A N/A N/A
VIP No VIP available No VIP available VKORC1 *2 N/A N/A N/A
VIP No VIP available No VIP available VKORC1 *3 N/A N/A N/A
VIP No VIP available No VIP available VKORC1 *4 N/A N/A N/A
No VIP available CA VA
rs1801272 NC_000019.10:g.40848628A>T, NC_000019.9:g.41354533A>T, NG_008377.1:g.6820T>A, NM_000762.5:c.479T>A, NP_000753.3:p.Leu160His, XM_005258568.1:c.326T>A, XP_005258625.1:p.Leu109His, rs111473904, rs17791931, rs4986890, rs56844942
A > T
SNP
L160H
No VIP available CA VA
rs28399433 NC_000019.10:g.40850474A>C, NC_000019.9:g.41356379A>C, NG_008377.1:g.4974T>G, NM_000762.5:c.-48T>G, XM_005258568.1:c.-48T>G, rs386508632, rs58538938
A > C
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs28399444
VIP No Clinical Annotations available No Variant Annotations available
rs7294 NC_000016.10:g.31091000C>T, NC_000016.9:g.31102321C>T, NG_011564.1:g.8956G>A, NM_001311311.1:c.*134G>A, NM_024006.5:c.*134G>A, NM_206824.2:c.*237G>A, XM_005255568.1:c.*134G>A, XM_011545816.1:c.-2191G>A, XM_011545817.1:c.-2191G>A, XM_011545818.1:c.-2191G>A, XM_011545819.1:c.-2191G>A, XM_011545820.1:c.-2191G>A, XM_011545943.1:c.*134G>A, XM_011545944.1:c.*134G>A, XM_011545945.1:c.*237G>A, XR_243303.1:n.1175G>A, XR_950848.1:n.1414G>A, rs17880624, rs59098562
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs9923231 NC_000016.10:g.31096368C=, NC_000016.10:g.31096368C>T, NC_000016.9:g.31107689C=, NC_000016.9:g.31107689C>T, NG_011564.1:g.3588G=, NG_011564.1:g.3588G>A, NM_001311311.1:c.-1639G=, NM_001311311.1:c.-1639G>A, NM_024006.5:c.-1639G=, NM_024006.5:c.-1639G>A, NM_206824.2:c.-1639G=, NM_206824.2:c.-1639G>A, XM_005255568.1:c.-1639G=, XM_005255568.1:c.-1639G>A, XM_011545943.1:c.-1639G=, XM_011545943.1:c.-1639G>A, XM_011545944.1:c.-1252G=, XM_011545944.1:c.-1252G>A, XM_011545945.1:c.-1252G=, XM_011545945.1:c.-1252G>A, XR_243303.1:n.-990G=, XR_243303.1:n.-990G>A, XR_950848.1:n.-31G=, XR_950848.1:n.-31G>A, rs117572127, rs17878363, rs60511154
C > A
C > G
C > T
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs9934438 NC_000016.10:g.31093557G>A, NC_000016.9:g.31104878G>A, NG_011564.1:g.6399C>T, NM_001311311.1:c.174-136C>T, NM_024006.5:c.174-136C>T, NM_206824.2:c.173+1000C>T, XM_005255568.1:c.174-136C>T, XM_011545943.1:c.174-136C>T, XM_011545944.1:c.174-136C>T, XM_011545945.1:c.173+1000C>T, XR_243303.1:n.823-236C>T, XR_950848.1:n.962-136C>T, rs17641219
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
Trade Names
Brand Mixture Names

PharmGKB Accession Id

PA134521193

Type(s):

Drug

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Chemical Properties

Isomeric SMILES

c1ccc2c(c1)ccc(=O)o2

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

No related drugs are available.

Curated Information ?

Publications related to coumarin: 39

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2016. Na Gao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antidotes to coumarins, isoniazid, methotrexate and thyroxine; toxins that work via metabolic processes. British journal of clinical pharmacology. 2015. Bateman D Nicholas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. British journal of clinical pharmacology. 2014. Verhoef Talitha I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Differential Effects of Nicotine Treatment and Ethanol Self-administration on CYP2A6, CYP2B6 and Nicotine Pharmacokinetics in African Green Monkeys. The Journal of pharmacology and experimental therapeutics. 2012. Ferguson Charmaine S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and genomics. 2012. McDonagh Ellen M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in spanish patients with thromboembolic disease. PloS one. 2012. Borobia Alberto M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of Coumarin Dosing: Prevalence of CYP2C9 and VKORC1 Polymorphisms in the Lebanese Population. Genetic testing and molecular biomarkers. 2011. Djaffar-Jureidini Isabelle, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes. Pharmacogenomics. 2011. Wang Huijuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Copy number variants in pharmacogenetic genes. Trends in molecular medicine. 2011. He Yijing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
VKORC1 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Owen Ryan P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro. Cancer chemotherapy and pharmacology. 2009. Jeong Seongwook, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics. 2009. van Schie Rianne M F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional characterization of CYP2A13 polymorphisms. Xenobiotica; the fate of foreign compounds in biological systems. 2007. Schlicht K E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of eleven isothiocyanates on P450 2A6- and 2A13-catalyzed coumarin 7-hydroxylation. Chemical research in toxicology. 2007. von Weymarn Linda B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2A6 polymorphisms: is there a role for pharmacogenomics in preventing coumarin-induced hepatotoxicity in lymphedema patients?. Pharmacogenomics. 2007. Farinola Nicholas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2006. Li Li, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochemical and biophysical research communications. 2006. Wang Jue, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics-based coumarin therapy. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2006. Gage Brian F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochemical pharmacology. 2005. Fukami Tatsuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nature structural & molecular biology. 2005. Yano Jason K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenetics and genomics. 2005. Haberl Michael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug metabolism and disposition: the biological fate of chemicals. 2005. Fukami Tatsuki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coumarins are competitive inhibitors of cytochrome P450 1B1, with equal potency for allelic variants. Pharmacogenetics and genomics. 2005. Mammen Jennifer S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics. 2003. Kiyotani Kazuma, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clinical pharmacology and therapeutics. 2003. Yoshida Ryoko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annual review of pharmacology and toxicology. 2003. Ding Xinxin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Human mutation. 2002. Oscarson Mikael, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochemical and biophysical research communications. 2002. Xu C, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochemical and biophysical research communications. 2001. Pitarque M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. The Journal of biological chemistry. 2001. Kitagawa K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug metabolism and disposition: the biological fate of chemicals. 2000. Donato M T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer research. 2000. Su T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica; the fate of foreign compounds in biological systems. 2000. Meunier V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS letters. 1999. Oscarson M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS letters. 1998. Oscarson M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1997. Hadidi H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. The Journal of pharmacology and experimental therapeutics. 1994. Shimada T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. The Biochemical journal. 1990. Miles J S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 1990. Yamano S, et al. PubMed

Clinical Trials

These are trials that mention coumarin and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.